Heron Q2 FY26 net loss widens to $5.49 million; net sales rise 1.3% to $37.67 million
HRTX•Q2 FY26 results
Heron Therapeutics posted Q2 2026 net sales of $37.7 million, up 9% from Q1 2026.
Net loss widened to $5.49 million; GAAP basic EPS was $(0.03).
Segment performance and outlook
Acute Care net sales rose 43.9% year-over-year to $15.33 million, led by APONVIE up 73.6% to $4.28 million.
Oncology net sales fell 15.9% year-over-year to $22.33 million, with CINVANTI down 9.7% to $21.79 million.
The company withdrew full-year 2026 guidance, citing uncertainty on generic entry timing for CINVANTI, paused salesforce expansion, and a strategic alternatives review.
